Kornimate/medical-research-clean huggingface dataset:
a study of an epstein-barr virus (ebv) candidate vaccine, mrna-1189, in 10- to 30-year-old healthy adolescents and adults

Conditions: Epstein-Barr Virus Infection

Summary: the main objective of part a of this trial is to evaluate the safety and reactogenicity of mrna-1189 in 18- to 30-year-old healthy adults, the main objective of part b is to evaluate the safety and reactogenicity of mrna-1189 in 12- to \<18-year-old healthy ebv-seronegative adolescents, and the main objective of part c is to evaluate the safety and reactogenicity of mrna-1189 in 10- to 21-year-old healthy adolescents and adults.


Eligibility criteria:
inclusion criteria: * according to the assessment of the investigator, is in good general health and can comply with study procedures. part a: healthy adult from 18 to 30 years of age (inclusive) at the time of consent (screening visit, day 0). part b: healthy baseline ebv-seronegative adolescents from 12 to \<18 years of age at the time of consent (screening visit, day 0). part c: healthy adolescents and adults from 10 to 21 years of age (inclusive) at the time of consent (screening visit, day 0). exclusion criteria: * has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection or covid-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against covid-19 at least 14 days prior to the screening visit. * has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). * significant, progressive, unstable or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures per investigator judgement. * has a history of myocarditis, and/or pericarditis. * has received or plans to receive any licensed or authorized vaccine, to include covid-19 vaccines, ≤28 days prior to the first injection (day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection. note: other inclusion and exclusion criteria may apply.

Keywords: infectious mononucleosis mononucleosis
accuracy of fnac in thyroid nodules compared to to surgical specimen : qoc experience

Conditions: Fine Needle Aspiration Cytology; Thyroid Diseases

Summary: thyroid gland diseases are the second most common endocrine disease following diabetes mellitus(1). thyroid nodules are common disorders with a prevalence ranged from 4 to 7% in adult population, 5%-30% are malignant \[1\].fine-needle aspiration cytology (fnac) is an easy, cost-effective test for cancer diagnosis, and its use has markedly decreased the number of unnecessary thyroid surgeries(2).

it should be noted that fnac cannot differentiate between benign and malignant follicular neoplasms.differentiation between follicular adenoma and follicular carcinoma is only possible after thyroid lobectomy.\[2,3\] in addition, a study of fnac showed that 68% of the cases diagnosed by fnac as follicular neoplasm turned out to be the follicular type of papillary carcinoma, indicting a considerable overlap between benign and malignant neoplasms.\[4\] incidental findings of thyroid nodules have increased exponen¬tially in recent years, mostly due to the widespread application of high-resolution ultrasound (us) to the thyroid \[5\].several in¬ternational scientific societies have established clinic-radiolog¬ical guidelines for the diagnosis and the management of thy¬roid nodules \[2,3\]. the american college of radiology identifies 5 radiological risk levels and recommends us-guided fine-nee¬dle aspiration cytology (us-fnac) of high-suspicion nodules if 10 mm or larger, and of nodules with a low risk for malignan¬cy only if larger than 25 mm \[2\]. according to the european thyroid association guidelines (eu-tirads), nodules with no high-risk features (oval-shaped, isoechoic/hyperechoic with smooth margins) should be considered at low risk and fna performed only if greater than 20 mm, while high-risk nodules greater than 10 mm should undergo fnac, with possible fnac also in 5-10 mm nodules if highly suspicious \[3\].

Eligibility criteria:
inclusion criteria: * thyroid diseases * multi nodullar * single nodules * diffuse goiter * thyroid diseases underwent fnac then thyroid surgery exclusion criteria: * patients with no diagnostic fnac

Keywords: fnac thyroid nodules thyroidectomy
study to determine the immunization status among nephrological health care personnel against sars-cov-2 in a single center over the course of 12 months during the worldwide covid-19 pandemic.

Conditions: SARS-CoV 2; Immunization; Infection

Summary: infections with corona-viruses have shown to be a menace for patients with comorbidities such as hypertension, diabetes, cardiovascular disease or immunosuppression. those are features almost every nephrological patient brings along, especially those on maintenance dialysis and those with renal transplant. since the emergence of the novel coronavirus sars-cov-2 in november 2019 in mainland china the fear for pandemic infections has increased. but not only is the course of infection itself important, the prevention of transmission to and by attending medical personnel should be put into perspective. thus there is a lack of sufficient data of occult immunization or persistent state on immunization. in our study up to 400 health care personnel will be screened serologically for igm, iga and igg against the sars-cov-2 virus. blood and urine samples throughout 12 months will be sampled and analyzed. the aim of the study is to identify the rate of occult immunization and at the same time to gather data about the persistence of immune response to an infection with sars-cov-02. the results will help provide sufficient safety measures for health care providers and renal patients undergoing unavoidable clinical treatment.


Eligibility criteria:
inclusion criteria: * health care personnel and other staff at the division of nephrology \& dialysis at the medical exclusion criteria: * not matching the inclusion criteria

Keywords: nephrology sars-cov-2 vienna health care personnel
evaluation of protein in the urine in patients receiving bevacizumab

Conditions: Colon Cancer; Rectal Cancer

Summary: this is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). there are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. we hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.


Eligibility criteria:
inclusion criteria: * patients must be 18 years older * patients must be receiving his/her first dose of bevacizumab * patients must sign an informed consent exclusion criteria: * patients receiving \> 10 mg/kg doses of bevacizumab

Keywords: bevacizumab proteinuria
cancer predictive score on breast mri

Conditions: Breast Cancer

Summary: sometimes, breast ultrasound and mammographic can't be diagnose suspsious lesions ( no substratum). so a mri-guided breast biopsy is perfomed and disclosed ultimately benign lesions. the aim of this retrospective study is to establish a predictive mri score of occult breast lesions by mammography and ultrasound.


Eligibility criteria:
inclusion criteria: * women aged 18 and more * performed mri-guided breast biopsy exclusion criteria: - not mri-guided breast biopsy

Keywords: women imaging diagnostic imaging magnetic resonance imaging breast biopsy breast cancer detection predictive factors radiology breast lesion diagnosis
combined use of a novel cardioplegic formula with mps® versus cardioplexol ® in urgent isolated cabg using miecc in patients with recent acute myocardial infarction

Conditions: Heart Attack; Cardioplegia Solution Adverse Reaction; Coronary Artery Bypass Grafting (CABG)

Summary: the goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of mps ® vs. cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.


Eligibility criteria:
inclusion criteria: * patients who underwent a cabg using mps® or cardioplexol ® * heart attack less than 7 days before surgery exclusion criteria: * use of other cardioplegia solution than cardioplexol ® or mps® * other inventions than cabg * explicit will of the patient that his data may not be used * denied general consent

Keywords: heart attack cardioplegia solution minimal extracorporeal circulation system (miecc) myocardial protection system (mps) coronary artery bypass grafting (cabg)
ketamine co-induction for patients with major depressive disorder

Conditions: Ketamine; Depression; Anesthesia

Summary: ketamine hydrochloride, an anesthetic medication, has been demonstrated to acutely and rapidly improve depressive symptoms but not yet been adequately studied for this effect when used as part of a general anesthetic for surgery. this proposed single-centre, double-blinded, randomized clinical trial of adult patients with depression presenting for gynecologic surgery would compare severity of depressive symptoms between patients receiving and not receiving ketamine as part of their general anesthetic.


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder * presentation for gynecologic surgery requiring a general anesthetic exclusion criteria: * marked co-morbid cardiovascular disease * marked co-morbid respiratory disease * history of intracranial hypertension * history of seizures * asa physical status classification iv or greater * history of psychosis * current pregnancy * contraindication to ketamine administration
conversion to monotherapy study with keppra xr for partial seizures

Conditions: Epilepsy

Summary: the primary objective of this study is to assess the efficacy of two doses of keppra xr compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.


Eligibility criteria:
inclusion criteria: * male or female subjects 12 to 75 years of age. * subjects must have inadequately controlled partial onset epilepsy. * subjects must be experiencing 2 to 40 seizures per 4-week period while being maintained on one or two standard aed(s) exclusion criteria: * a history of status epilepticus in the 6 months preceding randomization. * significant medical, psychiatric or neurological illness. * intake of benzodiazepines on more than an occasional basis * history of previous treatment with levetiracetam or sensitivity to levetiracetam.

Keywords: keppra xr conversion to monotherapy partial seizures
study in healthy volunteers to prove that 2 rotigotine patches from different manufacturing processes deliver equivalent drug amount to the body.

Conditions: Healthy

Summary: the major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing processes.


Eligibility criteria:
inclusion criteria: * healthy white, male volunteers between 18 and 55 years of age (inclusive). * bmi between 19 and 28 kg/m² (inclusive). exclusion criteria: * previous participation in a clinical study with rotigotine * history or current condition of epilepsy and/or seizures. * known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity. * history of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis. * history or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease. * clinically relevant abnormality in physical examination, ecg, vital signs or safety laboratory examinations. * positive hiv, hepatitis b or c test or positive alcohol or drug test. * relevant hepatic or renal dysfunction * intake of medication that might interfere with the test drug within 2 weeks prior to dosing. * thickly hair-covered abdomen resulting in difficulties in finding appropriate patch application sites

Keywords: rotigotine neupro® transdermal patch
pain, central sensitization, kinesiophobia and stress level in individuals with temporomandibular dysfunction

Conditions: Temporomandibular Joint Disorders; Pain

Summary: temporomandibular dysfunction (tmd) is a musculoskeletal and neuromuscular system-related condition that affects the masticatory muscles, temporomandibular joint, and other related structures. recent research has focused specifically on pain catastrophe, kinesiophobia, and central sensitization in individuals with tmd. therefore, the aim of this study is to examine the relationship between pain, central sensitization, kinesiophobia and stress level in individuals with temporomandibular dysfunction.

temporomandibular dysfunction (tmd) is a musculoskeletal and neuromuscular system-related condition that affects the masticatory muscles, temporomandibular joint, and other related structures. psychological factors are stated as comorbid in individuals with tmd. individuals with tmd-related pain show higher levels of stress, anxiety, depression, somatic awareness, pain catastrophizing, and kinesiophobia compared to controls. therefore, recent research has focused on pain catastrophe, kinesiophobia, and central sensitization, especially in individuals with tmd. therefore, the aim of this study is to examine the relationship between pain, central sensitization, kinesiophobia and stress level in individuals with temporomandibular dysfunction. ninety patients aged 18-65 years, who have tme-related complaints for at least 3 months, and diagnosed with tmd as a result of clinical and radiological evaluation by a dentist will be included in the study.

Eligibility criteria:
inclusion criteria: * between the ages of 18-65, * having complaints related to tmj for at least 3 months, * patients diagnosed with tmd as a result of clinical and radiological evaluation by the dentist exclusion criteria: * cognitive problems, * any systemic joint or muscle disease (e.g. fibromyalgia, rheumatoid arthritis), * serious systemic diseases, * any neurological disorder (e.g. trigeminal neuralgia), * pregnancy, breastfeeding status, * previous treatment for tmj or orofacial muscle pain

Keywords: temporomandibular joint dysfunction pain central sensitization kinesiophobia stress
inferior turbinate reduction in pediatric population failing surgery for sleep disordered breathing

Conditions: Sleep Related Breathing Disorder; Upper Airway Resistance Syndrome; Obstructive Sleep Apnea

Summary: this study will examine whether treatment of inferior turbinates in patients with continued symptoms of obstructive sleep apnea, sleep related breathing disorder, snoring, disturbed sleeping, open mouth breathing, and upper airway resistance syndrome after tonsillectomy and adenoidectomy will improve these symptoms and should be included in the treatment paradigm for treatment of sleep related breathing disorders in infants, children, and adolescents.

the question proposed by this study is one of treatment: to what extent does treatment of nasal obstruction from enlarged inferior turbinates with cold ablation inferior turbinate reduction in infants, children, and adolescents improve symptoms of obstructive sleep apnea, sleep related breathing disorder, snoring, disturbed sleeping, open mouth breathing, and upper airway resistance syndrome in patients that continue to have symptoms after tonsillectomy and adenoidectomy. the trial seeks to provide evidence that the treatment of inferior turbinates in patients with continued symptoms of obstructive sleep apnea, sleep related breathing disorder, snoring, disturbed sleeping, open mouth breathing, and upper airway resistance syndrome after tonsillectomy and adenoidectomy will improve these symptoms and should be included in the treatment paradigm for treatment of sleep related breathing disorders in infants, children, and adolescents.

Eligibility criteria:
inclusion criteria: 1. patients that underwent tonsillectomy and adenoidectomy for obstructive sleep apnea, sleep related breathing disorder, snoring, disturbed sleeping, open mouth breathing, and upper airway resistance syndrome with persistent symptomatology. 2. enlarged inferior turbinates with nasal obstruction (\>25%). 3. age 0-18 years. 4. lack of improvement of obstructive sleep apnea symptoms after maximal medical treatment with intranasal steroids in patients with symptoms of ars and h2 blocker medication in patients with symptoms of lpr. exclusion criteria: 1. previous adenotonsillar surgery or placement of tympanostomy tubes for recurrent otitis media, tonsillitis, or sinusitis. 2. patients with bmi \> 97% for age and sex. 3. patients with craniofacial abnormalities. 4. patients with previous airway issues, anatomic variance from normal, mallampati class iii or iv, septal deviation, choanal stenosis, and nasal stenosis.

Keywords: obstructive sleep apnea sleep related breathing disorder snoring disturbed sleeping open mouth breathing upper airway resistance syndrome
optical coherence tomography imaging in patients with acute myocardial infarction (optimal)

Conditions: Acute Myocardial Infarction

Summary: the purpose of the study is to investigate the clinical outcomes, safety and cost-effectiveness of intravascular oct imaging in patients with acute myocardial infarction undergoing percutaneous coronary intervention (pci). about 4500 patients with acute myocardial infarction (estimated 1500 with oct guidance and 3000 without oct guidance during pci）will be prospectively enrolled in 20 sites in china. the total duration of the study is expected to be 5 years, 2 years for enrolment and 3 years for follow up.

this is a prospective, multi-center, non-randomized, observational registry study of patients with acute myocardial infarction (ami) that require catheterization. the purpose of this registry is to investigate the clinical outcomes, safety and cost-effectiveness of intravascular oct imaging in patients with ami undergoing pci.the duration of the study is expected to be 5 years, 2 years for enrolment and 3 years for total follow up.the clinical study will be conducted in 20 centers in china.approximately 4500 subjects (1500 with oct imaging and 3000 without oct imaging) will be enrolled in this study.subjects will be followed up at 1, 3, 6, 12months and every 6 months afterwards up to 5 years. all subjects need to be followed for at least 12 months.

Eligibility criteria:
inclusion criteria: * patients presenting with:a.symptoms of myocardial ischemia lasting for ≥ 30 minutes.b.definite ecg changes indicating stemi: st elevation of greater than 0.1 mv in two contiguous limb leads or 0.2 mv in two contiguous precordial leads, or presumed new left bundle branch block. c. nstemi * referred for primary pci. * are able to provide written informed consent prior to any study related procedure. exclusion criteria: * patient who is unable to comply with the follow-up schedule. * left main occlusion * unable to restore timi flow grade iii before stenting * prior coronary artery bypass surgery (cabg) * cardiogenic shock * patient who has any medical conditions that in the opinion of the investigator will not be appropriate to participate in the study. * patient has a life expectancy of less than 6 month due to any condition. * age ≤ 18 years

Keywords: stemi nstemi
concomitant posterior colporrhaphy on bowel functions in pelvic organ prolapse repair

Conditions: Prolapse; Female

Summary: compare the changes of preoperative and postoperative posterior colporrhaphy.

introduction: concomitant posterior colporrhaphy was frequently used during pelvic organ prolapse repair. objectives: to evaluate the correlation between the presence of bowel symptoms and s rectocele severity and elucidate the impact of posterior colporrhaphy on bowel functions. methods: medical records of all consecutive women who received concomitant posterior colporrhaphy for their pelvic organ prolapse repairs were reviewed. in general, all women were requested to answer bowel incontinence assessment questionnaires before and after surgery. possible results: differences in rectocele severities between the presence or absence of fecal incontinence, flatus incontinence, constipation, diarrhea or sensation of residual stool will be shown.

Eligibility criteria:
inclusion criteria: * women with pelvic organ prolapse planned to receive concomitant posterior colporrhaphy exclusion criteria: * pregnancy
women at risk: the high risk breast cancer program

Conditions: Breast Cancer

Summary: the purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. data from this group will be collected and entered into a registry. this registry serves as a clinical database to support research in prevention, early detection and treatment of breast cancer.

this is a longitudinal cohort study that collects data of eligible women at risk for developing breast cancer. patient information will be entered into a secured computerized database that is used for research on the prevention, early detection and treatment of breast cancer.

Eligibility criteria:
inclusion criteria: * one or more first-degree relatives (mother, daughter, or sister) with pre-menopausal breast cancer * two or more first-degree relatives with post-menopausal breast cancer * tested positive for a brca1 or brca2 mutation * a history of biopsy-proven atypical ductal hyperplasia or atypical lobular hyperplasia * a history of biopsy-proven lobular neoplasia (lobular carcinoma in situ) exclusion criteria: * dcis (ductal carcinoma in situ) * previous diagnosis of breast cancer

Keywords: brca mutation benign breast disease family history of breast cancer strong family history of breast cancer atypical ductal hyperplasia atypical lobular hyperplasia high risk for breast cancer